Analyst Reco. Cabaletta Bio, Inc.

Equities

CABA

US12674W1099

Market Closed - Nasdaq Other stock markets 03:59:58 2024-05-06 pm EDT			5-day change	1st Jan Change
12.87 ^USD	+3.87%		+22.81%	-43.30%

Mar. 22	HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating	MT
Mar. 21	Cabaletta Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating	Mar. 22	MT
Jefferies Initiates Cabaletta Bio with Buy Rating, $36 Price Target	Feb. 05	MT
Morgan Stanley Cuts Price Target on Cabaletta Bio to $25 From $28 as FDA Probes T-Cell Malignancies in CAR-T Cell Therapy, Keeps Overweight Rating	Nov. 29	MT
Cantor Fitzgerald Adjusts Price Target on Cabaletta Bio to $50 From $40, Maintains Overweight Rating	Nov. 15	MT
HC Wainwright Adjusts Price Target on Cabaletta Bio to $25 From $17, Keeps Buy Rating	Nov. 10	MT
Cantor Fitzgerald Initiates Cabaletta Bio With Overweight Rating, Price Target is $40	23-10-24	MT
Stifel Starts Cabaletta Bio With Buy Rating, Price Target is $31	23-10-19	MT
Wells Fargo Raises Price Target on Cabaletta Bio to $39 From $14, Keeps Overweight Rating	23-09-18	MT
Citigroup Starts Cabaletta Bio at Buy With $22 Price Target	23-09-05	MT
HC Wainwright Adjusts Price Target on Cabaletta Bio to $17 From $15, Maintains Buy Rating	23-08-11	MT
Guggenheim Initiates Cabaletta Bio at Buy With $34 Price Target	23-07-18	MT
HC Wainwright Adjusts Price Target on Cabaletta Bio to $15 From $11, Maintains Buy Rating	23-03-17	MT
Morgan Stanley Upgrades Cabaletta Bio to Overweight From Equal Weight, $16 Price Target	23-01-27	MT
Wells Fargo Boosts Price Target on Cabaletta Bio to $14 From $4, Keeps Overweight Rating	23-01-03	MT
Chardan Trims Price Target on Cabaletta Bio to $12 From $13, Affirms Buy Rating	22-11-11	MT
Wells Fargo Adjusts Cabaletta Bio's Price Target to $4 From $14, Maintains Overweight Rating	22-09-14	MT
Morgan Stanley Downgrades Cabaletta Bio to Equalweight from Overweight, Adjusts Price Target to $3 from $15	22-08-30	MT
Chardan Research Adjusts Price Target on Cabaletta Bio to $13 From $17, Reiterates Buy Rating	22-08-12	MT
Mizuho Securities Adjusts Cabaletta Bio's Price Target to $10 From $20, Reiterates Buy Rating	22-05-25	MT
Evercore ISI Cuts Cabaletta Bio's Price Target to $15 From $20, Maintains Outperform Rating	22-03-18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Cabaletta Bio, Inc.

Equities

CABA

US12674W1099

Analyst Reco.

Filters